CAS 128794-94-5|Mycophenolate mofetil
| Common Name | Mycophenolate mofetil | ||
|---|---|---|---|
| CAS Number | 128794-94-5 | Molecular Weight | 433.495 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 637.6±55.0 °C at 760 mmHg |
| Molecular Formula | C23H31NO7 | Melting Point | 95-96ºC |
| MSDS | ChineseUSA | Flash Point | 339.4±31.5 °C |
| Symbol | GHS07, GHS09 | Signal Word | Warning |
Names
| Name | mycophenolate mofetil |
|---|---|
| Synonym | More Synonyms |
Mycophenolate mofetil BiologicalActivity
| Description | Mycophenolate Mofetil is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) with IC50s of 39 nM and 27 nM, respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Cancer |
| References | [1]. Nakanishi, T., et al., Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol, 2010. 10(1): p. 91-7. [2]. Dehghani, F., et al., Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant mycophenolate mofetil. Neuropathol Appl Neurobiol, 2010. 36(7): p. 598-611. [3]. Ozgen, M., et al., Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol, 2012. 37(1): p. 48-54. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 637.6±55.0 °C at 760 mmHg |
| Melting Point | 95-96ºC |
| Molecular Formula | C23H31NO7 |
| Molecular Weight | 433.495 |
| Flash Point | 339.4±31.5 °C |
| Exact Mass | 433.210052 |
| PSA | 94.53000 |
| LogP | 3.15 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.557 |
| InChIKey | RTGDFNSFWBGLEC-SYZQJQIISA-N |
| SMILES | COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)OCCN1CCOCC1)C(=O)OC2 |
| Storage condition | Store at RT |
Safety Information
| Symbol | GHS07, GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H400 |
| Precautionary Statements | P273 |
| Hazard Codes | Xn |
| Risk Phrases | R22 |
| Safety Phrases | 22 |
| RIDADR | UN 3077 9 / PGIII |
Articles130
More Articles| Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Transplantation 99(1) , 180-6, (2015) Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing st... | |
| Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation. J. Am. Coll. Surg. 219(6) , 1134-42.e2, (2014) Thoracic fluid retention after living donor liver transplantation (LDLT) has various negative consequences, including atelectasis, pneumonia, and respiratory distress or failure.We analyzed the clinic... | |
| The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression. Clin. Transplant. 28(8) , 845-54, (2014) Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and o... |
Synonyms
| 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)- |
| 6-((7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl))-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester |
| 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester |
| Cellcept |
| MYCOPHENOLATE MOFETIL EP IMPURITY A (= USD RC A) |
| 2-(Morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate |
| Mycophenolate mofetil (CellCept) |
| Mycophenolatemofetil |
| 2-morpholin-4-ylethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate |
| MYCOPHENOLATE MOFITILE |
| MYCOPHENOLATE |
| 2-(Morpholin-4-yl)ethyl-(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-methylhex-4-enoat |
| RS 61443-190 |
| MYCOPHENOLATE MOFETIL FOR PEAK IDENTIFICATION, EP STANDARD |
| 2-morpholin-4-ylethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate |
| (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester |
| (4E)-6-(4-hydroxy-6-méthoxy-7-méthyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-méthylhex-4-énoate de 2-morpholin-4-yléthyle |
| MYCOPHENALATE MOFETIL |
| 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate |
| 2-(4-Morpholinyl)ethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-4-hexenoate |
| 2-(4-Morpholinyl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-4-hexenoate |
| MYCOPHENOLATE MOFETIL(CELLCEPT) |
| (E)-2-morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate |
| 2-Morpholin-4-ylethyl-(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofur-5-yl)-4-methylhex-4-enoat |
| Mycophenolate mofetil |
| MFCD00867568 |
| Mycophenolic acid morpholinoethyl ester |
